Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
EAH.L
STRONG BUYFLAGECO Animal Health Group plc · Healthcare · United Kingdom · $78M · Avg Vol: $210K/d
ECO Animal Health has quality Q65 and value V71 with genuine insider buying of 0.03%, but momentum at M47 is below the calibrated floor, so stage one fails.
COMPANY DESCRIPTION
ECO Animal Health Group plc develops, registers, and markets high-quality pharmaceutical products for the global animal health sector, specializing in swine and poultry. Its flagship patented antibiotic, Aivlosin, is a global market leader in treating respiratory and enteric diseases in intensive livestock farming. The company maintains a strong competitive position through its extensive global regulatory approvals and a robust pipeline of vaccines.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 108.5M | 112.6M | 118.0M | 105.1M | -1.1% | 115.5M | 107.9M | 112.3M | 2.2% |
| EPS | -0.01 | 0.02 | 0.02 | 0.03 | 29.3% | 0.04 | 0.03 | 0.04 | 3.6% |
| Shares | 67.7M | 67.7M | 67.7M | 67.5M | -0.3% | 66.7M | — | — | — |
| Debt | 2.5M | 5.9M | 5.3M | 5.0M | 25.6% | 6.5M | — | — | — |
| Equity | 108.3M | 109.9M | 110.5M | 112.8M | 1.4% | — | — | — | — |
| Op CF | -0.7M | 21.0M | 12.4M | 13.8M | -19.0% | 10.1M | — | — | — |
| Inv CF | -3.6M | -7.8M | -4.5M | -6.1M | — | — | — | — | — |
| Fin CF | -4.4M | -3.2M | -4.9M | -2.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EAH.L are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| EAH.L | ECO Animal Health Group plc(you) | $78M | 95 | STRONG BUY |
| ANCR.L | Animalcare Group plc | $302M | 90 | STRONG BUY |
| PXS.L | Provexis plc | $39M | 44 | HOLD |
| STX.L | Shield Therapeutics plc | $86M | 21 | SELL |
| HIK.L | Hikma Pharmaceuticals PLC | $4.3B | 89 | STRONG BUY |
| KNSA | Kiniksa Pharmaceuticals International, plc | $4.8B | 87 | STRONG BUY |
| KOO.L | Kooth plc | $75M | 96 | STRONG BUY |
| BVXP.L | Bioventix PLC | $116M | 99 | STRONG BUY |
| SPEC.L | INSPECS Group plc | $140M | 81 | STRONG BUY |
| TSTL.L | TRISTEL PLC ORD 1P | $251M | 92 | STRONG BUY |
Peer medians: ROE -3.8% · P/E 24.4x · Gross margin 56.9%